The Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users (NCT07532460) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
The Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users
Switzerland40 participantsStarted 2026-04
Plain-language summary
The study aims to address the neurobiological basis of cognitive impairments in chronic cocaine users by investigating the potential impact of an acute potassium channel blockade on working memory performance and other cognitive functions.
Who can participate
Age range
20 Years – 50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Current diagnosis of mild, moderate, or severe CoUD according to DSM-5
* Minimum cocaine use of 1g/month in the last three months
* Cocaine as the primary drug of consumption
* Willingness to abstain from cocaine use at least 72 hours before prior to each study visit
* Ability to read, understand and provide written informed consent
* To be sufficiently fluent in German
* Age between 20 and 50 years
* Body mass index (BMI) between 19 and 30 kg/m2
* If applicable: luteal phase of the menstrual cycle
* For individuals with childbearing potential: use of contraceptive measures
Exclusion Criteria:
* Presence or history of severe neurological disorders or head injuries
* Current diagnosis of an acute or chronic infectious disease
* If applicable: pregnancy and breastfeeding
* Lifetime history of any epileptic seizures
* Lifetime diagnosis of a cardiovascular disease, specifically arrhythmia and long QT syndrome
* Clinically significant laboratory or ECG abnormality that could be a safety issue in the study
* Lifetime diagnosis of liver or kidney disease including moderate or severe renal impairment (creatinine clearance \< 50 ml/min)
* Known hypersensitivity or allergy to 4-aminopyridine
* Use of potassium channel blockers within the last 3 months
* Use of psychotropic medication within the last 7 days
* Use of inhibitors of the organic cation transporter 2 (OCT2), such as cimetidine
* Lifetime diagnosis of schizophrenia, bipolar disorder, obsessive-compul…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Global Working Memory Performance
Timeframe: Baseline and during both experimental sessions
Trial details
NCT IDNCT07532460
SponsorBoris Quednow
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2027-08
Contact for this trial
Prof. Dr. rer. nat. Boris B. Quednow, Dr. rer. nat.